Conferences

Bringing together the healthcare ecosystems of France, Germany, and Switzerland, the Health Innovation Nexus is the leading trinational event for innovation and collaboration in the Upper Rhine region. It connects companies, hospitals, universities, research organizations, public authorities, and innovation stakeholders to exchange ideas, spark partnerships, and shape the future of healthcare. Discussions will focus on emerging technologies, health data, European health policy, resilience, supply chains, and cross-border cooperation. A dedicated B2B matchmaking platform will enable participants to build valuable connections and launch new collaborative projects across borders.

Representatives from Venture Valuation and Biotechgate will participate in this event.

BIO-Europe is Europe’s largest and longest-running partnering conference for the global biotechnology and biopharma industry. The event brings together 5800+ participants from more than 3,200 companies across 60+ countries, to build partnerships, share insights, and explore business opportunities in life sciences.

Representatives from Venture Valuation and Biotechgate will participate in this event.

LSX Investival Showcase London brings together biotech innovators, medtech pioneers, healthcare investors and corporate strategics from across Europe and beyond, creating a dynamic environment for investment discussions, partnering opportunities and business development. For life science companies, the Investival Showcase offers a valuable opportunity to build visibility with the European and global market, pitch to active investors and build new connections through organised partnering and networking opportunities. Taking place on the first day of London Life Science Week, it's growing in size and scale. It's the first and biggest public event of the week, open to the wider life science community, and offers full partnering facilities to all attendees. Get a 15% discount to LSX Investival Showcase Europe by using the promo code: VENTUREVALUATION15.

Representatives from Venture Valuation and Biotechgate will participate in this event.

AutomaPlus 2026 (Zurich, 16-17 November) focuses on digital instruments for the pharma industry. The agenda covers AI, Pharma 4.0, digital factories and GxP-ready solutions, with participants from GSK, Takeda, Novartis, WHO, Emerson and others.

The Creative Disruption Forum is a high-level, interactive gathering built for executive leaders, senior researchers, startup founders, and biotech investors.

The Quantum Horizon Meets Real-World Science

We are witnessing a transformative shift in health innovation. While emerging paradigms like quantum computing promise to fundamentally redefine how we process biological complexity in the future, biopharma leaders today need actionable, deployable technologies to de-risk pipelines, accelerate drug discovery, and improve clinical outcomes now.

The Latest & Future Technologies Impacting Health Innovation and Life Sciences bridges the gap between tomorrow’s deep-tech horizons and today’s high-impact biological and computational breakthroughs. Hosted at ARC West London as a flagship London Life Sciences Week event, this interactive forum brings together biopharma executives, tech bio founders, investors, and academic leaders for unscripted, Chatham House Rules discussions on what is genuinely working, where the bottlenecks lie, and how to build scalable healthcare solutions.

From physical molecule-to-protein target engagement (such as CETSA® platforms) and human-relevant New Approach Methodologies (NAMs) to real-world AI applications in lead optimization, this event delivers an unfiltered "boots on the ground" look at modern translational science.

A thought leadership workshop for Business & Research Leaders from life sciences innovation companies and investors

• Are you a business leader of a Life Science Innovation company or investor?
• Are you interested in discussing current dealmaking and investment strategies that are working?
• Do want to learn more about other people's experiences, or share your thoughts and queries around investment & dealmaking?
• Are you looking to learn from, and meet with, your peers and experienced industry professionals and seasoned investors?

What are the Dealmaking & Investment Strategies that are working?

The life sciences and biotech sector is currently grappling with a range of investment challenges shaped by regulatory pressures, evolving market dynamics, and shifting public sentiment. As the industry strives to recover from the pandemic’s disruption, deal-making has become more cautious and complex, reflecting the demand for robust compliance and transparency.

One significant challenge is the increased regulatory scrutiny following COVID-19. Investors are now prioritizing companies with clear pathways to regulatory approval and validated clinical data. This trend influences venture capital flows, as investors seek to minimize risk by backing firms with established compliance measures. Smaller biotech companies, in particular, face hurdles in securing funding, as they often lack the resources to navigate the intricate regulatory landscape effectively. Moreover, public perception regarding drug pricing and access is steering investment decisions. Investors are more inclined to support companies that align their missions with social responsibility and ethical practices.

This societal lens encourages firms to develop narratives that emphasize not only financial viability but also positive community impact, a factor that is increasingly crucial in attracting committed investors. To address these challenges, strategic partnerships are emerging as a vital solution. Collaborations between small biotech startups and larger pharmaceutical firms can enhance credibility and access to resources, providing a safety net for navigating regulatory complexities.

Additionally, the use of non-dilutive funding—such as grants and government contracts—has gained traction, allowing companies to focus on long-term innovations without immediate financial pressures.In this evolving landscape, investment strategies that embrace transparency, collaboration, and ethical considerations will be pivotal. As the life sciences sector adapts, innovative approaches will unlock new opportunities for growth, ensuring a sustainable path forward for the future of healthcare.

Green-Shoots? We will explore what is happening in Europe and the US with experts that know the activity in the financial marketplace. We will have Bill Hicks with us from Mintz in Boston, US along with James Fry from Mills & Reeve who has his finger on the pulse regarding the UK and EU markets, along with other experts.

BioPharma Deals Conference 2026 is a focused gathering for the biopharma dealmaking community, bringing together senior professionals from biotech and pharmaceutical companies, investors, advisors, and other key industry stakeholders to explore opportunities across business development, licensing, strategic partnerships, investment, M&A, and co-development. The event will feature: High-level networking with senior industry professionals Curated one-to-one partnering meetings Discussions on business development, licensing, investment, and strategic transactions Opportunities to connect with biotech innovators, pharma leaders, investors, and advisors A focused platform for developing meaningful business and dealmaking connections

Biotechgate Digital Partnering is a virtual conference designed to support the business development of Biotech, Medtech and Pharma companies. Join five days of digital partnering and establish new global connections thanks to pre-arranged one-on-one Zoom meetings, along with informal networking events and workshops.

Representatives from Venture Valuation and Biotechgate will participate in this event.

The RESI Conference will be held on January 11-12 at the San Francisco Marriott Marquis, featuring two days in-person event followed by three days (January 13, 18 & 19) of online partnership activities. Previous RESI JPM conferences have drawn over a thousand attendees, including more than 600 early-stage life science investors, innovators, and industry experts. This RESI is held concurrently with JP Morgan Healthcare Week. As the largest and most comprehensive healthcare investment symposium, it attracts thousands of life science professionals globally.

Get $300 off registration by using the code: BTG

Representatives from Venture Valuation and Biotechgate will participate in this event.

Biotech Showcase is a premier investor conference committed to creating a platform for private and micro-mid-cap biotechnology companies, offering them a unique opportunity to showcase their innovations and engage one-to-one with investors and biopharmaceutical executives.

Representatives from Venture Valuation and Biotechgate will participate in this event.

The J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.

Set in one of Europe's leading life sciences hubs, the Basel conference explores how drug discovery can scale through advanced technologies, European investment, strategic partnerships, and cross-border collaboration.

BIO-Europe Spring is Europe's largest springtime biotech partnering event, bringing together over 3,700 leaders and innovators in the life sciences industry. It's designed for partnering, business development, and licensing opportunities in biotechnology and pharmaceuticals.

Representatives from Venture Valuation and Biotechgate will participate in this event.

Created in partnership with the Kobe Biomedical Innovation Cluster (KBIC), RESI Asia Japan is the gateway connecting early-stage life science companies with Japan’s leading pharmaceutical giants and global capital. Following RESI Boston and RESI JPM, this premiere event completes a 7-month global partnering cycle, offering fundraising startups unparalleled access to licensing deals, cross-border investment syndicates, and Asia’s largest life science market.

Representatives from Venture Valuation and Biotechgate will participate in this event.

The Swiss Biotech Day conference celebrates the power of international collaboration, driving innovation, partnerships and global impact. Since 2021, the Swiss Biotech Day has grown by an average of 35% every year, establishing itself as one of the world’s premier biotechnology conferences. It brings together life sciences leaders from across the globe to spark collaboration, innovation and meaningful partnerships. In 2026, the event welcomed more than 3,500 participants from 58 countries, including 31 international delegations, a testament to its global reach and impact. It was by far the biggest and most international edition of the Swiss Biotech Day ever. Join the Swiss Biotech Day to network, exchange ideas and explore advances in R&D, manufacturing, data management, AI and innovative financing. In addition, the embedded Global Village provides international delegations a platform to strengthen their ties with the Swiss biotech hub to promote cross-border investments, public-private partnerships, R&D collaborations and the exchange of best practices.

Representatives from Venture Valuation and Biotechgate will participate in this event.

The ChinaBio® Partnering Forum is a leading event for cross-border partnering, giving the global biopharma community the chance to expand its presence in China's life-sciences market through unrivalled cross-border partnering. Engage with the largest network of potential partners to accelerate cross-border strategies and grow your presence in the Chinese market.

Representatives from Venture Valuation and Biotechgate will participate in this event.

The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from around the world.

Representatives from Venture Valuation and Biotechgate will participate in this event.